FDA Approves APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplant for Multiple Myeloma Patients (https://www.myeloma.org/news-events/multiple-myeloma-news/fda-approves-aphexda-myeloma)